Glioblastoma Multiforme (GBM) Treatment Market Report 2025 – Strategic Insights for Companies Seeking Expansion, Growth & Competitive Advantage
Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts
What are the growth projections for the glioblastoma multiforme (gbm) treatment market from 2024 to 2029?
The glioblastoma multiforme (GBM) treatment market size has grown rapidly in recent years. It will grow from $2.48 billion in 2024 to $2.74 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increased incidence and prevalence, advancements in diagnostic techniques, clinical trials and research funding, collaborations and partnerships, improved understanding of tumor biology.
The glioblastoma multiforme (GBM) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.1 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to emergence of immunotherapies, precision medicine advancements, expanded knowledge of genetic markers, patient advocacy and awareness, government support for rare diseases. Major trends in the forecast period include exploration of combination therapies, integration of artificial intelligence in diagnosis and treatment planning, rise in adoption of immunotherapeutic approaches, advance medical tools and equipment.
Download Your Free Sample PDF:
What strategic initiatives by market players are driving glioblastoma multiforme (gbm) treatment industry growth?
The increasing prevalence of brain disorders is expected to propel the growth of the glioblastoma multiforme (GBM) treatment market going forward. Brain disorders refer to abnormal functioning of the brain as well as the nerves found throughout the human body and the spinal cord. The increasing prevalence of brain disorders such as glioblastoma multiforme (GBM) is due to various contributing factors such as the aging population, compromised immune systems, overdiagnosis, ionizing radiation, air pollution, and others which creates the need for the treatment of brain disorders to improve well-being. For instance, according to a report published by the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, in 2022, around 25,050 malignant tumors of the brain or spinal cord cancer cases were diagnosed in the US. Therefore, the increasing prevalence of brain disorders is driving the growth of the glioblastoma multiforme (GBM) treatment market.
What emerging segments are shaping the future landscape of the glioblastoma multiforme (gbm) treatment industry?
The glioblastoma multiforme (GBM) treatment market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Targeted Therapy: EGFR Inhibitors, Other Targeted Agents
5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
6) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies
View The Full Market Report:
Which sustainability trends are emerging in the glioblastoma multiforme (gbm) treatment market?
Major companies operating in the market are focused on development of innovative wearable and portable devices to sustain their position in the market. These advancements aim to offer users enhanced functionality, convenience, and comfort, catering to the growing demand for accessible and efficient healthcare solutions. For instance, in 2023, Novocure, a Jersey-based oncology company, launched Optune Gio, a wearable and portable treatment system for patients with newly diagnosed glioblastoma (GBM), approved by the FDA. This device employs Tumor Treating Fields (TTFields), which are alternating electric fields that disrupt cancer cell division, potentially extending patient survival. Weighing only 2.7 pounds, Optune Gio is designed for comfort, allowing patients to wear it during daily activities.
How are key players in the glioblastoma multiforme (gbm) treatment market strengthening their market position?
Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.
Which geographic areas are contributing significantly to the growth of the glioblastoma multiforme (gbm) treatment sector?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Glioblastoma Multiforme (GBM) Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Glioblastoma Multiforme (GBM) Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment